HK Stock Market Move | Asymchem Laboratories (06821) rose over 5% in the afternoon session, with a significant increase in gross profit margin from new businesses in the first half of the year. It is expected that the delivery of orders on hand this year will drive accelerated growth.

Asymchem Laboratories (06821) rose over 5% in the afternoon, hitting a 5.53% increase to HKD 130.4 as of this writing, with a transaction volume of HKD 120 million. In news, Asymchem Laboratories recently disclosed its mid-year performance for 2026. BOCOM INTL pointed out that the company's revenue and adjusted net profit for the first half of 2026 both increased by 13% year-on-year. The revenue from the company's emerging business surged by 72%, with gross margin significantly rising to 32.5%; revenue from large molecule chemistry, biopharmaceutical CDMO, and formulation businesses grew by 94%/123%/51%. Management maintained its revenue growth guidance for the year at 19-22%. BOCOM INTL indicated that Asymchem Laboratories' order backlog in the first half of 2026 increased by 54% year-on-year, with new contracts signed in the first eight months of 2026 up by 55%. Management expects approximately 85% of the backlog will revenue in the second half of 2026 to 2027. Among them, the backlog for large molecules increased by 164%, with projects related to peptide weight reduction and PPQ projects rising to 25 and 8 respectively, while oligonucleotide and payload-linker projects rapidly advanced to the later/PPQ stage. The company has raised its full-year capital expenditure guidance to HKD 2.6-2.8 billion, which will increase further to HKD 3 billion in 2027, with a focus on large molecule chemistry and biopharmaceuticals.